Savara (SVRA) Retained Earnings (2010 - 2026)
Savara (SVRA) reported Retained Earnings of -$429000.0 for Q1 2026, up 32.12% year-over-year from -$324704.2 in Q1 2025, and down 393.1% quarter-over-quarter from -$87000.0 in Q4 2025.
Savara (SVRA) Retained Earnings (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Retained Earnings data on file, last reported at -$429000.0 in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$429000.0, up 32.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$429000.0 (up 32.12% YoY), and the FY2025 annual result was -$87000.0, up 88.4% from the prior year.
- Retained Earnings declined to -$429000.0 in Q1 2026 per SVRA's latest filing, from -$87000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at -$87000.0 in Q4 2025 and troughed at -$575.9 million in Q3 2025.
- A 5-year average of -$178.3 million and a median of -$750000.0 in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings slumped 115317.89% in 2022, then jumped 99.71% in 2023.
- A 5-year view of Retained Earnings shows it stood at -$605000.0 in 2022, then jumped by 55.21% to -$271000.0 in 2023, then slumped by 176.75% to -$750000.0 in 2024, then soared by 88.4% to -$87000.0 in 2025, then tumbled by 393.1% to -$429000.0 in 2026.
- Business Quant data shows SVRA's Retained Earnings at -$429000.0 in Q1 2026, -$87000.0 in Q4 2025, and -$575.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -838.07 Mn |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | -429,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -429,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -575.85 Mn |
| Jun 30, 2025 | -546.30 Mn |
| Mar 31, 2025 | -632,000.00 |
| Dec 31, 2024 | -750,000.00 |
| Sep 30, 2024 | -460.21 Mn |
| Jun 30, 2024 | -435.96 Mn |
| Mar 31, 2024 | -742,000.00 |
| Dec 31, 2023 | -271,000.00 |
| Sep 30, 2023 | -942,000.00 |
| Jun 30, 2023 | -360.67 Mn |
| Mar 31, 2023 | -461,000.00 |
| Dec 31, 2022 | -605,000.00 |
| Sep 30, 2022 | -328.37 Mn |
| Jun 30, 2022 | -317.99 Mn |
| Mar 31, 2022 | -291,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | 285,000.00 |
| Jun 30, 2021 | -278.67 Mn |